Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech
Pharmaceutical Technology
NOVEMBER 26, 2024
Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.
Experimental Alzheimer’s Vaccine Shown to Delay Symptoms in Mice
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 3, 2023
An experimental vaccine that aims to slow down or prevent the progression of Alzheimer’s disease has been trialed in mice with promising early results. Mice engineered with genes that put them at greater risk of an Alzheimer’s-like disease had fewer amyloid plaques following the vaccine.
Vaccine 
246
246 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Radical Vaccine Strategy Could Help Quash Parasite Afflicting Millions
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 11, 2024
Using viruses that infect bacteria to detect proteins sprouted by a notorious parasite, scientists have honed in on possible vaccine targets for schistosomiasis, a neglected tropical disease that currently affects an estimated 600 million people worldwide, causing 280,000 deaths per year.
Vaccine 240
240 
Malaria Could Be Eliminated by 2040: New Vaccine Offers Hope
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 8, 2023
The World Health Organization has approved a new vaccine that scientists argue will be a game-changer in the fight against malaria, which kills half a million people in Africa every year.
Vaccine 246
246 
BioNTech Founders Predict Cancer Vaccine Is Only Years Away
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 16, 2022
The husband-and-wife team who co-founded BioNTech, the biotechnology company that partnered with Pfizer to develop an effective messenger-RNA (mRNA) shot against COVID-19, has predicted that a cancer vaccine could be widely available within the next decade.
Vaccine 242
242 
Extreme Case of Man Who Had 217 COVID Vaccines Surprises Scientists
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 12, 2024
That’s how many vaccines a man in Germany claims to have received for COVID-19 in just 29 months – and his body isn’t reacting the way some scientists thought it would. Two hundred and seventeen. The 62-year-old male from the city of Magdeburg made headlines a few years ago for his private and risky decision […]
Scientist 246
246 
India’s success story in pediatric vaccination program should be further replicated in adult vaccination: Experts
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 28, 2023
India’s success story in pediatric vaccination programme should be further replicated in the form of adult vaccination programme, experts recommended on the occasion of the 2nd edition of the India Vaccine Leaders Conclave (IVLC) held between August 22 and August 23, 2023 under the theme “Building Resilient Vaccine Ecosystems” in Mumbai.
Vaccine 189
189 
SEC recommends permission to SII for Omicron XBB 1.5 variant Covid-19 vaccine
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 14, 2024
A Subject Expert Committee (SEC), which advices the national drug regulator on approvals and clinical trials related to Covid-19 vaccines, has recommended grant of permission to Serum Institute of India (SII) for Omicron XBB 1.5 The vaccine variant […]
Vaccine 189
189 
ICMR and Panacea Biotec initiate phase 3 clinical trial for the first indigenous dengue vaccine, DengiAll
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 19, 2024
The Indian Council of Medical Research (ICMR) and Panacea Biotec have announced the initiation of the first-ever phase 3 clinical trial for a dengue vaccine in India. The trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec.
Clinical Trials 189
189 
SEC recommends approval for Zydus Lifesciences’ trivalent influenza vaccine in children
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 13, 2024
The Subject Expert Committee (SEC), which advises the Central drug regulator regarding clinical trials and approvals of drugs, has recommended approval for additional indication of Zydus Lifesciences’ inactivated trivalent influenza vaccine in children above six months with clinical trial waiver subject to condition.
Vaccine 188
188 
Examining COVID’s impact on clinical research participant diversity
pharmaphorum
FEBRUARY 21, 2022
The clinical research industry has long struggled with participant diversity. One study found that only 5% of Black or Asian United Kingdom residents had ever participated in a clinical trial. A study of FDA-approved vaccine trials from 2011-2020 showed that 78% of participants were white, even though only 60% of the U.S.
DBT to support multi institutional CoEs for nano-vaccines and nano-adjuvants development
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 14, 2022
The Department of Biotechnology (DBT) is extending support to the institutions and scientists to set up Centres of Excellence in the country for nano-vaccines and nano-adjuvants, to treat cancer and other diseases.The Department has invited Letters of Intent (LoIs) for ‘Setting up of CoE in Nano-Vaccines & Nano-Adjuvants’ for a period of five years (..)
Vaccine 189
189 
IISc develops heat-tolerant vaccine for protection against different strains of SARS-CoV-2 & future variants
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 22, 2024
The Indian Institute of Science (IISc) is now developing a heat-tolerant vaccine that can offer protection against different strains of SARS-CoV-2 – both current and future variants. The research […]
Vaccine 188
188 
IXCHIQ Chikungunya Vaccine Trial Shows Sustained Immune Response in Adolescents
XTalks
JANUARY 22, 2025
Valneva SE, who developed the worlds first FDA-approved chikungunya vaccine , has now unveiled promising Phase III data for its single-shot chikungunya vaccine, IXCHIQ, in adolescents aged 12 to 17. IXCHIQ is the only licensed chikungunya vaccine in the US for adults aged 18 and older at increased risk of exposure to the virus.
PETA India urges CPCSEA to withdraw recommendation for using stray dogs for vaccine testing
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 17, 2022
Animal rights organisation People for Ethical Treatment of Animals (PETA) India has urged the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) to withdraw its recent recommendations for using stray dogs for vaccine testing in favour of superior, human-relevant, animal-free research methods, which are more effective (..)
Vaccine 189
189 CDSCO declares sample of Bharat Biotech’s typhoid vaccine Typbar as NSQ
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 11, 2023
The Central Drugs Standard Control Organisation (CDSCO) has declared a batch of Typbar, the typhoid polysaccharide vaccine from Bharat Biotech International Ltd as not of standard quality (NSQ).
Vaccine 180
180 
DoP rejects Bharat Serums and Vaccines’ review petitions on ceiling price fixation of Hucog HP
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 25, 2023
The Department of Pharmaceuticals (DoP) has rejected review applications filed by the Maharashtra-based Bharat Serums and Vaccines Ltd against National Pharmaceutical Pricing Authority (NPPA) fixing the ceiling price of its infertility treatment drug brand Hucog HP, since the company did not file the petition within the prescribed time limit.
Vaccine 187
187 
Primary care sites: A new avenue for clinical research
pharmaphorum
MARCH 1, 2022
The primary care setting offers huge potential for commercial research. This was, and still is being, demonstrated through the UK’s COVID-19 vaccine research successes. Primary care sites require their own approach, but they can have great benefits for clinical trial recruitment, access to hard-to-reach patients, and more.
Propelling clinical research into the 21st century
pharmaphorum
NOVEMBER 15, 2022
A renaissance in vaccines research is just one example of something good to come out of the pandemic. For the clinical trials industry, the pandemic forced new ways of working and fresh ways of thinking about clinical research and how to conduct it remotely.
Velocity Nominated for Two 2025 Vaccine Industry Excellence (ViE) Awards
Velocity Clinical Research
FEBRUARY 11, 2025
Velocity is a nominee for two 2025 Vaccine Industry Excellence (ViE) Awards! After winning the Best Clinical Trial Company ViE Award in 2024, we would be honored to receive your vote and once again share this recognition with you as we work to improve vaccine trials worldwide.
Vaccine 52
52 
Small Study Reveals How The Pandemic Impaired Babies’ Social Development And Behavior
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 13, 2023
COVID sent us into a series of lockdowns in a bid to control the spread of the virus until a vaccine could be developed. Most of us knew that a vaccine would be the key to our post-pandemic […] The world changed for all of us when we were suddenly plunged into a pandemic in 2020.
Development 244
244 
Covid vaccine booster raises antibody levels in fight against Omicron
pharmaphorum
JANUARY 21, 2022
A third dose of vaccine has been shown to effectively neutralise the Omicron variant of covid-19, according to researchers. Research led by UCLH, UCL and the Francis Crick Institute found that the booster dose successfully stimulates antibody levels that neutralise Omicron. Overall, antibody levels were nearly 2.5
Antibody 115
115 
Charles Eger, MD, Authors New Article in Nature Medicine
Velocity Clinical Research
MARCH 19, 2025
Charles Eger, MD, contributed to new research on a combination vaccine intended to provide protection against both seasonal flu and COVID-19 in a single shot. Full article: [link] The post Charles Eger, MD, Authors New Article in Nature Medicine appeared first on Velocity Clinical Research.
Medicine 52
52 
The Benefits of Working for a Rapidly Growing Global Clinical Research Organization (CRO) like Medpace
XTalks
OCTOBER 18, 2022
A clinical research organization (CRO) is a company that delivers outsourced services to plan, manage and execute clinical trials for biotechnology, pharmaceutical, and medical device companies. Read on to learn why life science and clinical research professionals are choosing a career with Medpace. Cardiovascular.
Disease X: WHO Warns Future Outbreak Just a Matter of Time
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 21, 2024
With a fatality rate 20 times that of COVID-19, and no vaccine, Disease X could swiftly bring humanity to its knees. Few would be left untouched by the pathogen were it to gain hold, causing healthcare systems to crumble and economies to collapse as the world once again tried to contain a force of nature. […]
Containment 245
245 
WHO Ranks The Deadliest Pathogens, Including The Mysterious ‘Disease X’
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 24, 2022
The WHO said the aim was to update a list used to guide global research and development (R&D) and investment, especially in vaccines, tests, and […].
Vaccine 245
245 
Can You Exercise After Flu Shot? What About Other Vaccines?
DM Clinical Research
SEPTEMBER 29, 2020
Annual flu shots are very important, as are other vaccines. While vaccines are quick and easy, they sometimes might require a little down-time. If you are dealing with a headache, fever, or nausea after your vaccine, then it is best to skip the gym. Are Vaccine Side Effects Normal? Vaccines Matter- Now More than Ever.
Vaccine 75
75 
COVID-19 vaccine development: Safety monitoring continues revolution in RWD
pharmaphorum
JULY 1, 2021
Miruna Sasu lays out how real-world data is evolving in the post COVID-19 vaccine reality. . Only a year after the emergence of COVID-19, a handful of life science companies started publishing data on the encouragingly high efficacy of their vaccine candidates. The speed with which these vaccines came to the public is remarkable.
Vaccine 103
103 
GSK’s Maria Reyes Boceta-Muñoz Talks Vaccine Development in a Post-Pandemic World
XTalks
SEPTEMBER 5, 2023
Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals. What are the major challenges you’re facing right now in vaccine development?
Vaccine 96
96 
Thermo Fisher continues to expand clinical research capacity with $59m lab expansion
Outsourcing Pharma
OCTOBER 31, 2022
Thermo Fisherâs clinical research subsidiary, PPD, invests $59 million in sample management and testing capacity for vaccines and cell and gene therapy products with its expansion of laboratory operations in Kentucky.
Kaiser Permanente Joins Late-Stage Trial for Pfizer and BioNTech’s Lead COVID-19 Vaccine Candidate
XTalks
AUGUST 13, 2020
As the rush for a COVID-19 vaccine continues, healthcare services company Kaiser Permanente has joined in on the clinical testing of Pfizer Inc. and BioNTech’s lead vaccine candidate in a Phase III trial being conducted at sites in California and Oregon.
Vaccine 89
89 
Latin America’s Continuous Cultural Exchange and Contribution to Clinical Research
WCG Clinical
OCTOBER 8, 2024
Latin America’s genetic diversity and unique health challenges are driving groundbreaking clinical research, offering new insights into disease prevention, innovative medicine, and treatments. 4] Cultural Exchange and Medicine Vaccines are an example of how cultural exchange and collaboration shape global health advancements.
Experimental COVID-19 vaccine offers long-term protection against severe disease
Medical Xpress
DECEMBER 1, 2022
In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)
Vaccine 74
74 
Behind the Scenes with a Study Coordinator for a Potential Breakthrough Breast Cancer Vaccine
ACRP blog
OCTOBER 10, 2023
In recognition of October being Breast Cancer Awareness Month , ACRP recently went behind the scenes with a clinical research coordinator on the study team for a bold Cleveland Clinic investigation of a vaccine aimed at preventing triple-negative breast cancer (TNBC), the most aggressive and lethal form of the disease.
Vaccine 111
111 
Pharma Mirror Q&A with Jane Myles, Vice President of Clinical Trial Innovation at Curebase
Pharma Mirror
JANUARY 23, 2023
This webinar focused on the need for a coordinated clinical trials enterprise, one that can quickly characterize emerging viral threats and evaluate the effectiveness of vaccines, therapeutics, and other countermeasures across a diversity of trial participants.
Clinical Trials 147
147 
Researchers at IISc develop novel method to deliver vaccine candidate for TB
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 22, 2022
The Indian Institute of Science (IISc), Centre for BioSystems Science and Engineering, has designed a new method to deliver a vaccine candidate for tuberculosis (TB). The research involves using spherical vesicles secreted by bacteria coated on gold nanoparticles which can then be delivered to the immune cells.
Vaccine 100
100 
The Start of Germany’s National Pharma Strategy: Implications for CROs and Clinical Trials
Velocity Clinical Research
NOVEMBER 12, 2024
Aiming to revitalize the country’s pharmaceutical industry, it signaled a shift from policymakers on clinical research and drug development issues. The strategy outlined several measures to address the country’s declining role in global clinical trials, safeguard pharmaceutical supply chains, speed up approvals, and reduce bureaucracy.
Centre notifies Rules for CCSEA with provisions for deemed approval & grading of animal house facilities
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 12, 2023
The Central government has notified the administrative Rules for the Committee for Control and Supervision of Experiments on Animals (CCSEA), the statutory Committee to regulate and monitor experiments on animals to prevent cruelty to animals, with provisions for deemed approval and grading of animal house facilities in medical colleges, pharmacy colleges, (..)
Pharmacy 189
189 
Delhi HC quashes NPPA orders on overcharging against Bharat Serums and Vaccines and Bard Healthcare
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 28, 2022
The Delhi High Court has quashed four demand notices raised by the National Pharmaceutical Pricing Authority (NPPA) against Bharat Serums and Vaccines Ltd and medical devices manufacturer Bard Healthcare India Pvt Ltd for overcharging on non-scheduled drugs and medical devices, finding the move as unjustifiable as it does not allow rounding off principle (..)
Vaccine 100
100 
STAT+: Pfizer scraps half of participants in Lyme disease drug trial due to quality issues
STAT News
FEBRUARY 17, 2023
Pfizer and partner Valneva are scrapping data from roughly half of the participants in a Phase 3 trial of a Lyme disease vaccine candidate after uncovering quality issues with a third-party clinical trial operator.
Trials 119
119 
Video: Vaccine CARE Council Leader Mark Turner, MD
Velocity Clinical Research
MAY 21, 2024
“Next to clean water, vaccines are probably responsible for more saved lives than anything else we’ve done in medicine.” ” -Mark Turner, MD, Vaccine CARE Council Leader and Velocity Principal Investigator in Boise, ID.
Vaccine 52
52 
NIHR reveals phase 1/2 trial to evaluate an investigational vaccine for mpox in the UK
Pharma Times
MARCH 15, 2024
More than 3,700 cases of mpox have been identified in the UK since May 2022
Vaccine 153
153 
Gritstone bio trumpets first data for ‘multivariant’ COVID jab
pharmaphorum
JANUARY 5, 2022
A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial. “But it may be; and if it doesn’t other novel vaccines with similar benefits may well take on this role.”
Protein 126
126 
Video: Vaccine CARE Council Leader Shishir Khetan, MD
Velocity Clinical Research
APRIL 24, 2024
He’s also a leading expert for the Vaccine CARE Council. But as he explains in this video, he’s excited about the opportunities the CARE Council model is creating for investigators, even beyond vaccines. Shishir Khetan , MD, is a Principal Investigator and Senior Medical Director at Velocity.
Vaccine 52
52 
Let's personalize your content